On the other hand, PEBP1 was shown to act as an adverse prognostic factor in brain cancer (meningioma), colorectal cancer, breast cancer, ovarian cancer, and AML and a protective prognostic factor in bladder cancer, lung cancer, adenocarcinoma, and liposarcoma (Table S5). Here, PEBP1 is linked to ovarian cancer.